Sanctuary Advisors LLC Makes New Investment in Dynavax Technologies Co. (NASDAQ:DVAX)

Sanctuary Advisors LLC purchased a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,243 shares of the biopharmaceutical company’s stock, valued at approximately $182,000.

A number of other institutional investors and hedge funds also recently modified their holdings of DVAX. Vanguard Group Inc. raised its position in shares of Dynavax Technologies by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 9,275,788 shares of the biopharmaceutical company’s stock worth $129,676,000 after purchasing an additional 128,897 shares during the period. Congress Asset Management Co. MA raised its holdings in Dynavax Technologies by 1.3% during the 1st quarter. Congress Asset Management Co. MA now owns 229,980 shares of the biopharmaceutical company’s stock worth $2,854,000 after buying an additional 2,845 shares during the period. Diversified Trust Co lifted its stake in Dynavax Technologies by 3.2% during the first quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock valued at $367,000 after buying an additional 925 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Dynavax Technologies by 19.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 140,622 shares of the biopharmaceutical company’s stock valued at $1,745,000 after buying an additional 22,548 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Dynavax Technologies by 4.2% in the first quarter. Principal Financial Group Inc. now owns 767,909 shares of the biopharmaceutical company’s stock worth $9,530,000 after buying an additional 31,002 shares during the period. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Trading Up 0.3 %

NASDAQ:DVAX opened at $10.95 on Monday. The stock’s 50-day moving average is $11.05 and its two-hundred day moving average is $11.26. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18. The stock has a market cap of $1.43 billion, a PE ratio of 182.50 and a beta of 1.37. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.15.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. The firm had revenue of $73.80 million for the quarter, compared to the consensus estimate of $76.92 million. During the same period in the previous year, the firm posted $0.03 earnings per share. As a group, equities research analysts forecast that Dynavax Technologies Co. will post 0.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on DVAX. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a report on Tuesday, October 15th. The Goldman Sachs Group cut their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Dynavax Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $23.67.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.